Optomed: Q2’22 Report Comment - Redeye

Redeye provides its comments on Optomed’s Q2’22 report. We note that Optomed had lower sales than last year’s second quarter but that the company believes in a stronger second half of the year. However, we will publish a research update in the next couple of weeks, taking the information from the report into account and providing an updated view of the case. For now, we reiterate our Base Case of EUR 13.

Länk till analysen i sin helhet: https://www.redeye.se/research/849958/optomed-q222-report-comment?utm_source=finwire&utm_medium=RSS